Insmed Acquired intangibles decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Acquired intangibles shows an upward trend with a 11.0% CAGR.
Higher values indicate active inorganic growth strategies and significant capital deployment toward external intellectual property.
The total value of finite-lived intangible assets acquired during the period, typically through business combinations or...
Standard line item in cash flow statements under 'Investing Activities' for most acquisitive companies.
other_finitelived_intangible_assets_acquired1| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $29.60M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $30.00M | $15.00M | $0.00 |
| QoQ Change | — | — | -100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -50.0% | -100.0% |
| YoY Change | — | — | — | — | — | -100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 |
|---|---|---|---|---|---|---|---|
| AstraZeneca milestone | — | — | — | — | $11.25M | $11.25M | $11.25M |
| PARI milestones | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $30.00M |